Oliver Fox, you forgot the 70 percent sell off was b/c of a self imposed trial halt on PEGPH20 for clotting. Since then they added low molecular weight Heparin (a blood thinner) and trial is back on track. Recent run up was b/c of release of new data from that trial which was great. Also, now PEG has orphan status in US and EU. CEO Helen Torley says HALO is meeting with FDA late Q1/2015 to seek registration trial. Could be granted breakthrough status. On top of that, Enhanze platform generating expanding licensing income while PEG trials continue. HALO is in much better shape than when it was an $18 stock and I foresee share price reflecting that by June.
Latest Comments
Halozyme Therapeutics: A Good Bet To Get Back To Previous Highs
Oliver Fox, you forgot the 70 percent sell off was b/c of a self imposed trial halt on PEGPH20 for clotting. Since then they added low molecular weight Heparin (a blood thinner) and trial is back on track. Recent run up was b/c of release of new data from that trial which was great. Also, now PEG has orphan status in US and EU. CEO Helen Torley says HALO is meeting with FDA late Q1/2015 to seek registration trial. Could be granted breakthrough status. On top of that, Enhanze platform generating expanding licensing income while PEG trials continue. HALO is in much better shape than when it was an $18 stock and I foresee share price reflecting that by June.